by International Society of Glomerular Disease
A bite-size podcast brought to you by the International Society of Glomerular Disease. Nephrologists and glomerular disease experts Dr. Kenar Jhaveri (Northwell Health/Hofstra University) and Dr. Koyal Jain (UNC Chapel Hill) take a lighthearted look at the latest research, discuss clinical practice, and interview leaders in glomerular medicine — all in a short enough time to listen on your coffee break.
Language
🇺🇲
Publishing Since
9/2/2023
Email Addresses
1 available
Phone Numbers
0 available
March 7, 2025
<p>In this special NephMadness 2025 episode, Koyal and Kenar do a deep dive into the Genetics region with NephMadness executive team member Elena Cervantes (Johns Hopkins), genetics expert Jordan Nestor (Columbia) and region writer Matt Gross (Johns Hopkins). Genetics in FSGS faces off vs. Genetic Counseling! What’s new in our ever-expanding knowledge of FSGS genetics? Where does APOL1 fit in? How should we be counseling patients before and after genetic testing, and are we actually getting the training we need to do so? And the big question: Which topic will change practice the most in the next five years? Tune in and then cast your NephMadness vote! <a href="https://ajkdblog.org/2025/03/01/welcome-to-nephmadness-2025/">https://ajkdblog.org/2025/03/01/welcome-to-nephmadness-2025/</a></p><p><br></p>
September 15, 2024
<p>In this special bonus episode of the podcast, Koyal and Kenar provide a maximally useful review of minimal change disease, from diagnosis (including secondary causes to screen for) to treatment options, including how to decide which patients may do better with which therapies. </p><p>Can’t get enough minimal change? Check out Episode 6 (with Astrid Weins) and Episode 7 (with Felicitas Hengel and Nicola Tomas) for more on the potential role of anti-nephrin autoantibodies in MCD.</p><p><br></p><p><strong>References<br></strong><br></p><p><strong>KDIGO guidelines: </strong><a href="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GD-Guideline-Key-Takeaways-for-Clinicians-Minimal-Change-Disease.pdf">https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GD-Guideline-Key-Takeaways-for-Clinicians-Minimal-Change-Disease.pdf<br></a><br></p><p><strong>Anti-nephrin autoantibodies:<br></strong><br></p><p>Kronbichler A, Barnini C, Matyjek A, Gauckler P, Bruchfeld A, Caravaca-Fontan F, Floege J, Frangou E, Mirioglu S, Moran SM, Stevens KI, Teng YKO, Steiger S. Antibody-mediated podocytopathies: a disease entity that implies immunotherapy. Nephrol Dial Transplant. 2024 Jul 17:gfae166. doi: 10.1093/ndt/gfae166. Epub ahead of print. PMID: 39020250.</p><p>Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, Ronco P, Vivarelli M, Gesualdo L, Tomas NM, Huber TB; International Society of Glomerular Disease. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2314471. Epub ahead of print. PMID: 38804512.</p><p> </p><p>Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, Waikar SS, Chandraker A, Riella LV, Alexander MP, Troost JP, Chen J, Fermin D, Yee JL, Sampson MG, Beck LH Jr, Henderson JM, Greka A, Rennke HG, Weins A. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol. 2022 Jan;33(1):238-252. doi: 10.1681/ASN.2021060794. Epub 2021 Nov 3. PMID: 34732507; PMCID: PMC8763186.</p><p> </p>
July 15, 2024
<p>SHOW NOTES</p><p> </p><p>In this episode, Koyal and Kenar recap everything you need to know about IgAN for the board exam (or just to refresh yourself on the current state of knowledge) — from pathophysiology to treatment decisions. They also discover that nobody is really sure how to pronounce Peyer’s patches (hey, don’t blame us, they’re all the way over in the ileum) so make sure you read the show notes to settle that mystery and check out additional resources!</p><p> </p><p><strong>Board Review Bonus #1 - IgA Nephropathy</strong></p><p> </p><p><strong>Online calculator to predict progression (International IgAN Prediction Tool at biopsy - Adults)</strong></p><p><a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults">https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults</a> </p><p> </p><p><strong>Inflammatory bowel disease and IgAN:</strong></p><p>Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study. J Am Soc Nephrol. 2021 Feb;32(2):411-423. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33177116/">doi: 10.1681/ASN.2020060848</a>. Epub 2020 Nov 11. PMID: 33177116; PMCID: PMC8054887.</p><p> </p><p>MEST-C (Oxford classification): </p><p>Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-1021. <a href="https://www.kidney-international.org/article/S0085-2538(17)30101-1/fulltext">doi: 10.1016/j.kint.2017.02.003</a>. Epub 2017 Mar 22. PMID: 28341274.</p><p> </p><p><strong>DAPA-CKD: </strong></p><p>Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. <a href="https://www.nejm.org/doi/10.1056/NEJMoa2024816">doi: 10.1056/NEJMoa2024816</a>. Epub 2020 Sep 24. PMID: 32970396.</p><p> </p><p><strong>EMPA-Kidney: </strong></p><p>The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/">doi: 10.1056/NEJMoa2204233</a>. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.</p><p> </p><p><strong>STOP-IgAN trial: </strong></p><p>Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36. <a href="https://www.nejm.org/doi/10.1056/NEJMoa1415463">doi: 10.1056/NEJMoa1415463</a>. PMID: 26630142.</p><p> </p><p><strong>TESTING trial:</strong></p><p>Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022 May 17;327(19):1888-1898. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115617/">doi: 10.1001/jama.2022.5368</a>. PMID: 35579642; PMCID: PMC9115617.</p><p> </p><p><strong>Phase 3 trial of targeted-release budesonide (NefIgArd): </strong></p><p>Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023 Feb;103(2):391-402. <a href="https://www.kidney-international.org/article/S0085-2538(22)00836-5/fulltext">doi: 10.1016/j.kint.2022.09.017</a>. Epub 2022 Oct 19. PMID: 36270561.</p><p> </p><p><strong>MAIN trial:</strong></p><p>Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N; MAIN Trial Investigators. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open. 2023 Feb 1;6(2):e2254054. <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.54054">doi: 10.1001/jamanetworkopen.2022.54054</a>. PMID: 36745456.</p><p> </p><p><strong>A note on pronunciation:</strong> We dug a little deeper after recording this, and following the people they’re named after, <a href="https://www.kidney-international.org/article/S0085-2538(15)55087-4/fulltext">Jean Berger</a> (a French speaker) and <a href="https://www.gastrojournal.org/article/S0016-5085(05)01108-X/fulltext">Johann Conrad Peyer</a> (a German speaker), “Berger” should rhyme with “hooray” and “Peyer” should rhyme with “fire.” The more you know!</p><p> </p><p><strong>Disclosures:</strong> </p><p> </p><p>ISGD receives general financial support from Boehringer Ingelheim, Travere Therapeutics, and Calliditas Therapeutics, among other companies, through <a href="https://www.is-gd.org/partners">corporate partnerships</a>. None of these entities was involved in or had any influence on the content or editing of this episode.</p><p> </p><p>Koyal Jain serves as principal site investigator for Kaneka’s FSGSALLAGE (NCT04065438) and FSGS Pediatric (NCT02235857) clinical trials. </p><p> </p><p>Kenar Jhaveri is the National Scientific Lead for Otsuka's VISIONARY trial for IgA Nephropathy, and serves as a consultant for Otsuka, Novartis, and Calliditas.</p><p> </p><p> </p><p><strong> <br></strong><br></p>
Channel Your Enthusiasm
NephJC Team
Core IM Team
CardioNerds
The Curbsiders Internal Medicine Podcast
The Clinical Problem Solvers
American Society of Nephrology
Thomas Watchman
JAMA Network
BMJ Group
AccessMedicine
Dr. Anton Helman
Scott D. Weingart, MD FCCM
JAMA Network
American Academy of Family Physicians
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.